ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01144780
Recruitment Status : Terminated
First Posted : June 16, 2010
Last Update Posted : July 1, 2016
Sponsor:
Information provided by (Responsible Party):
Stanford University

Brief Summary:
The objective of this study is to better understand the underlying pathogenetic mechanisms of MPDs. We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.

Condition or disease
Myeloproliferative Disorders Myeloproliferative Disorders (MPD)

Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry
Study Start Date : September 2009
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Biospecimen Retention:   Samples Without DNA
blood and bone marrow


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).
Criteria

Inclusion Criteria:Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).

Exclusion Criteria:Any patient who is not willing to give consent.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01144780


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Jason Robert Gotlib Stanford University
Principal Investigator: Stephen Tracy Oh Stanford University

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01144780     History of Changes
Other Study ID Numbers: HEMMPD0011
SU-07092009-3060 ( Other Identifier: Stanford )
First Posted: June 16, 2010    Key Record Dates
Last Update Posted: July 1, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Disease
Myeloproliferative Disorders
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases